| RRC ID |
43640
|
| 著者 |
Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Mori S, Kamihira S, Tomonaga M, Miyazaki Y.
|
| タイトル |
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
|
| ジャーナル |
Int J Hematol
|
| Abstract |
The T315I BCR-ABL mutation in chronic myelogenous leukemia (CML) patients is responsible for up to 20% of all clinically observed resistance. This mutation confers resistance not only to imatinib, but also to second-generation BCR-ABL tyrosine kinases, such as nilotinib and dasatinib. A number of strategies have been implemented to overcome this resistance, but allogeneic stem cell transplantation remains the only established therapeutic option for a cure. A 61-year-old male was diagnosed with Philadelphia chromosome-positive chronic-phase CML in 2002. He was initially treated with imatinib and complete cytogenetic response (CCyR) was achieved 12 months later. However, after 18 months, a loss of CCyR was observed and a molecular study at 24 months revealed a T315I mutation of the BCR-ABL gene. At 30 months, imatinib/interferon-alfa (IFNα) combination therapy was initiated in an effort to overcome the resistance. Thirty months later, he re-achieved CCyR, and the T315I BCR-ABL mutation disappeared at 51 months. To our knowledge, this is the first case report showing the effectiveness of imatinib/IFNα combination therapy for CML patients bearing the T315I BCR-ABL mutation.
|
| 巻・号 |
95(2)
|
| ページ |
209-13
|
| 公開日 |
2012-2-1
|
| DOI |
10.1007/s12185-012-1005-1
|
| PMID |
22262141
|
| MeSH |
Antineoplastic Agents / administration & dosage
Benzamides
Drug Therapy, Combination
Fusion Proteins, bcr-abl / genetics*
Humans
Imatinib Mesylate
Immunologic Factors / administration & dosage
Interferon-alpha / administration & dosage*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Male
Middle Aged
Piperazines / administration & dosage*
Point Mutation
Pyrimidines / administration & dosage*
Treatment Outcome
|
| IF |
2.245
|
| 引用数 |
22
|
|
WOS 分野
|
HEMATOLOGY
|
| リソース情報 |
| ヒト・動物細胞 |
Ba/F3(RCB0895) |
